A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the current study is to determine whether Ataciguat (HMR1766) slows
progression of valve calcification in patients with moderate calcific aortic valve stenosis.
Secondary and tertiary objectives are to determine whether Ataciguat slows progression of
aortic valve function, reduces systemic inflammation, and prevents left ventricular
dysfunction in patients with moderate calcific aortic valve stenosis.